Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Finished Goods for 3 consecutive years, with $1.4 million as the latest value for Q1 2026.

  • For Q1 2026, Finished Goods rose 1284.0% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $1.4 million, up 1284.0%, while the annual FY2025 figure was $1.6 million, 4386.11% up from the prior year.
  • Finished Goods hit $1.4 million in Q1 2026 for Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $2.2 million in Q2 2025 and bottomed at $36000.0 in Q4 2024.
  • Average Finished Goods over 3 years is $1.3 million, with a median of $1.5 million recorded in 2025.
  • Year-over-year, Finished Goods surged 4386.11% in 2025 and then skyrocketed 1284.0% in 2026.
  • Syndax Pharmaceuticals' Finished Goods stood at $36000.0 in 2024, then soared by 4386.11% to $1.6 million in 2025, then decreased by 14.3% to $1.4 million in 2026.
  • According to Business Quant data, Finished Goods over the past three periods came in at $1.4 million, $1.6 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.